First HD multifocal lens for presbyopia and astigmatism

Article

opcon has launched the LENTIS Mplustoric intraocular lens (IOL.

Topcon has launched the LENTIS Mplustoric intraocular lens (IOL, designed to provide astigmatic patients the advanced benefits of Topcon's patented high-definition LENTIS Mplus technology. The company will officially present the lens to the market at the United Kingdom & Ireland Society of Cataract & Refractive Surgeons (UKISCRS) meeting in Brighton 11-12 November.

The LENTIS Mplustoric combines Topcon's LENTIS Mplus lens with the toric functionalities of the Tplus series. The LENTIS Mplus, which launched in July 2009, has been fitted in over 3,000 patients across the UK. Clinical trials have shown a reported rate of 95% patient satisfaction. Unlike other multifocal IOLs (MIOLs), it has a unique sector-shaped near-vision segment and uses only one transition zone, allowing, claims Topcon, for seamless transition between the near, intermediate and far vision zones and minimal to no risk of halos and glare in patient vision.

Professor Sunil Shah, Consultant Ophthalmologist at the Midland Eye Institute comments: “The LENTIS Mplustoric is simply the best all-in-one lens solution combining presbyopia correction with astigmatism. It is a major technical step forward for the IOL industry as it is the best combination of two highly advanced technologies. This lens has enabled us to better correct the vision of a wider range of patients and the outcomes have so far been remarkable.”

Gloria McCall, Topcon Surgical adds, “Topcon is excited about the launch of the LENTIS Mplustoric and looks forward to presenting it to the UK's top ophthalmologists at the UKISCRS meeting in November. The new lens offers high-definition glass-free vision to patients who would previously not have been suitable for our leading LENTIS Mplus design.”

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.